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PCardiac Surgery
lasma Tissue Factor Plus Activated
eripheral Mononuclear Cells Activate
actors VII and X in Cardiac Surgical Wounds
akashi Hattori, MD,* Mohammad M. H. Khan, MD, PHD,† Robert W. Colman, MD,†
. Henry Edmunds, JR, MD*
hiladelphia, Pennsylvania
OBJECTIVES The purpose of this study was to test the hypothesis that activated monocytes with soluble
plasma tissue factor (pTF) activate factors VII and X to generate thrombin.
BACKGROUND Despite heparin, thrombin is progressively generated during cardiac surgery with cardiopul-
monary bypass (CPB), produces intravascular fibrin and fibrinolysis, and causes serious
thromboembolic and nonsurgical bleeding complications. Thrombin is primarily produced in
the surgical wound, but mechanisms are unclear.
METHODS In 13 patients, interactions of mononuclear cells, platelets, pTF, and pTF fractions to activate
factors VII and X were evaluated in pre-bypass, perfusate, and pericardial wound blood before
and during CPB.
RESULTS Monocytes are activated in wound, but not in pre-bypass or perfusate plasma (monocyte
chemotactic protein-1  29.5  2.1 pmoles/l vs. 2.8  1.2 pmoles/l and 3.3 1.4 pmoles/l,
respectively). Wound pTF is substantially elevated compared to other locations (3.64  0.45
pmoles/l vs. 0.71  0.65 pmoles/l and 1.31  1.4 pmoles/l). Supernatant wound pTF
contains 81.7% of TF antigen; wound microparticle pTF contains 18.3%. Wound monocytes
and all C5a-stimulated monocytes (but not activated platelets) completely convert factor VII
to factor VIIa with wound pTF. Activated monocytes more efficiently activate factor X with
wound supernatant TF/factor VII(VIIa) complex than with wound microparticle TF/factor
VII(fVIIa). The correlation coefficient (r) between wound thrombin generation (F1.2) and
wound pTF concentration is 0.944 (p  0.0004).
CONCLUSIONS During cardiac surgery with CPB, wound monocytes plus wound pTF or wound
microparticle-free supernatant pTF preferentially accelerate activation of factor VII and factor
X. This system represents a novel mechanism for thrombin generation via the TF coagulation
pathway. (J Am Coll Cardiol 2005;46:707–13) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.040Cardiology Foundation
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wuring cardiac surgery using cardiopulmonary bypass
CPB), thrombin is progressively generated to produce a
onsumptive coagulopathy that is responsible for the
hromboembolic and nonsurgical bleeding complications
ssociated with these operations (1–5). The majority of
hrombin is produced in the pericardial wound (3,6), but
he timing and amounts of thrombin produced are not
ully explained by cell-bound tissue factor (TF) expres-
ion (6 –10).
Soluble plasma tissue factor (pTF) is an undefined mix-
ure of procoagulant microparticles (0.1 to 1 m) and
ossibly procoagulant protein fragments of TF (6,9,11).
ithin 15 min of starting CPB, Phillippou et al. (6) found
ncreased concentrations of soluble plasma tissue factor
From the *Harrison Department of Surgical Research, School of Medicine,
niversity of Pennsylvania, Philadelphia, Pennsylvania; and the †Sol Sherry Throm-
osis Research Center, Hematology Division of the Departments of Medicine and
hysiology, Temple University, Philadelphia, Pennsylvania. This work was supported
y grant HL47186 from the National Heart, Lung, and Blood Institute, National
nstitutes of Health, Bethesda, Maryland. Drs. Hattori and Khan contributed equally
o this project. Drs. Colman and Edmunds are equal senior authors.p
Manuscript received February 24, 2005; revised manuscript received April 28,
005, accepted May 3, 2005.pTF) and evidence of factor VII (fVII) activation and
hrombin formation in the pericardial wound. Earlier,
ieuwland et al. (9) demonstrated elevated concentrations
f procoagulant microparticles, primarily derived from
latelets and erythrocytes, in pericardial wound blood dur-
ng cardiac surgery; later studies confirmed the procoagulant
ctivity of microparticles (10).
The roles of blood cells, microparticles, and pTF in
hrombin generation in the pericardial wound is not clear.
hung et al. (8) observed more monocyte procoagulant
ctivity, fVII activation, and thrombin generation in the
ound than in the circulating perfusate. Shibamiya et al.
12) found more neutrophils and monocytes positive for TF
ntigen in pericardial blood than in the perfusate.
Monocytes synthesize TF, but peak concentrations occur
2 h after in vitro endotoxin stimulation, and only a third of
eak is reached within 2 h (13). Therefore, TF synthesis
oes not explain the rapid increase in monocyte procoagu-
ant activity in the pericardial wound (8). This study tests
he hypothesis that cardiac surgery with CPB-activated
ound monocytes that have not synthesized TF provides a
referred phospholipid platform for increased concentra-
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Monocytes and Plasma TF Activate Factors VII and X August 16, 2005:707–13ions of pTF that activate fVII and factor X (fX) to initiate
hrombin generation by the extrinsic coagulation pathway.
The results show that wound monocytes combined with
he supernatant fraction of wound pTF more rapidly and
ompletely activate fVII and fX than does the microparticle
raction. In this system activated monocytes, as compared to
ctivated platelets, more completely convert fVII to fVIIa.
ETHODS, MATERIALS, AND PATIENTS
ample sources and processing. Thirteen patients (three
omen) who required cardiac surgery with cardiopulmonary
ypass consented to donate 120 ml of blood/perfusate
uring operation after approval by the Institutional Review
oard (protocol #703385). The perfusion circuit included a
entrifugal pump and Maxima oxygenator (Medtronic Car-
iopulmonary, Anaheim, California) and was primed with
L Normosol-R, (Abbott Laboratories, North Chicago,
llinois). Activated clotting times were maintained 400 s
ith bovine lung heparin. Pericardial blood (mean hemat-
crit 20  1.8) was aspirated from the wound, washed
Haemonetics Inc., Braintree, Massachusetts), and rein-
used as packed red cells.
The mean age of the patients was 65.1  15.4 years
median 60 years, range 34 to 82 years); two were insulin-
ependent diabetics and three were smokers. Operations
ere first-time myocardial revascularization (n  5), single
r double valve repair or replacement (n  3), valve
eplacement with myocardial revascularization (n  2),
ortic replacement graft (n 2), and reoperative myocardial
evascularization (n  1). Cardiopulmonary bypass lasted
52  67 min. Blood samples were obtained from three
ocations: the arterial catheter after heparin, before CPB
pre-bypass), and simultaneously from the pericardial
ound (pericardial) and perfusion circuit (perfusate) 30 to
5 min after starting CPB. Additional blood samples were
btained from aspirin-abstaining volunteer donors.
ells. Citrated (3.8%, 9:1 vol) blood samples (20 to 40 ml)
ere centrifuged at 1,500 g for 20 min at 23 °C to separate
ells and plasma, which was then frozen at70 °C. Platelets
ere isolated from blood by Mustard’s method (14). Resus-
ended cellular pellets (25 mmol/l HEPES in Hank’s Buffer
alt Solution (1:1 vol/vol) were layered onto a Histopaque-
Abbreviations and Acronyms
CPB  cardiopulmonary bypass
ELISA  enzyme-linked immunosorbent assay
fVII  factor VII
fX  factor X
IgG  immunoglobulin G
MpTF  tissue factor on plasma microparticles
PTF  soluble plasma tissue factor
spTF  tissue factor in plasma supernatant
TAT  thrombin antithrombin complex
TF  tissue factor077 gradient (Sigma Chemical, St. Louis, Missouri) to asolate viable (by trypan blue exclusion test) mononuclear
ells (15).
Donated platelets were activated by the thrombin activa-
ion peptide derived from Par 1, SFLLRN-NH2 (Bachem
nc., King of Prussia, Pennsylvania), after a dose/response
rial, which showed aggregation within 10 min with 50
moles/l and none at 45 min with 20 or 10 moles/l.
ononuclear cells isolated from blood samples and donated
ononuclear cells were activated by incubation with recom-
inant human complement C5a (70 g/ml [Sigma Chem-
cal Co.] incubated at 37 °C for 60 min in HBSS buffer).
issue factor (TF). An Imubind Tissue Factor enzyme-
inked immunosorbent assay (ELISA) kit (American Diag-
ostica Inc., Greenwich, Connecticut) was calibrated by
tandard TF antigen (American Diagnostica Inc.).
nzyme-linked immunosorbent assay was used to measure
F antigen in all forms of TF, including TF/fVII(fVIIa)
omplex; soluble plasma tissue factor (pTF) taken from each
f three locations (pre-bypass, perfusate, and pericardium),
nd fractions of pTF: microparticle-bound pTF (mpTF)
nd pTF in supernatant plasma (spTF). Recombinant TF
as used as a standard; the curves of recombinant TF and
TF were parallel.
ractionation of soluble plasma tissue factor (pTF). Cir-
ulating microparticles present in plasma were isolated as
escribed previously (16). Briefly, 10 aliquots of 250 l of
lasma in 1-ml tubes were centrifuged for 30 min at 17,570
in a SORVALL superspeed RC 2-B automatic refriger-
ted centrifuge (Dupont, Wilmington, Delaware) at 23 °C.
he microparticle pellet was recovered and washed once
ith phosphate-buffered saline. The pellet was dissolved
ith 500 l of buffer (10 mM HEPES, 5 mM KCL, 1 mM
gCl2, and 136 mM NaCl; pH 7.4). Microparticles de-
ived from 5.0 ml of plasma were analyzed. Tissue factor
ntigen bound to microparticles (mpTF) and spTF were
easured by ELISA.
Wound pTF (but not pre-bypass or perfusate plasma)
ractionation was further evaluated. One milliliter of wound
TF was diluted with buffer (1:1 vol) (10 mM HEPES, 5
M KCL, 1 mM MgCl2, and 136 mM NaCl; pH 7.4) and
entrifuged at 260,000 g for 4 h (17). A microparticle pellet
nd three distinct particle-free fractions were separated (17).
he particle-free fractions were a floating lipid layer; a
iddle clear aqueous fraction; and a lower pigmented
tratum, which had the highest concentration of TF anti-
en. Microparticle pellets were washed once with
hosphate-buffered saline and dissolved in 500 l of buffer.
easurements of factors VIIa and Xa. Purified plasma
VII (lot CP2052U, Cortex Biochem Inc., San Leandro,
alifornia), of which 98% was in a single band on
DS-polyacrylamide gel electrophoresis, was used. Factor
IIa (fVIIa) was measured by chromogenic assay (Spec-
rozyme fVIIa; American Diagnostica Inc.). Specificity for
VII was verified using recombinant fVII (gift of Dr.
odney Camire); recombinant TF (10 nmoles/l) did notffect the assay (0.01 to 10 nmoles/l fVIIa). The assay was
f
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August 16, 2005:707–13 Monocytes and Plasma TF Activate Factors VII and Xree of fXa contamination as tested using fXa substrate,
-2765 Chromogenix, (Diapharma Group Inc., West
hester, Ohio). Below 1.0 nmole/l, fXa does not cleave
VIIa substrate.
Factor X activation by microparticle pTF or supernatant
TF with either unstimulated or C5a-stimulated mononu-
lear cells (2  106/ml) from each of the three sample
ocations was assessed. Cells were incubated with fVII (10
moles/l), CaCl2 (5 mmoles/l), and supernatant pTF (2.0
l) or microparticle pTF (2.0 ml) from pre-bypass, pericar-
ial wound, or perfusate samples for 10 min at 37°C. Factor
(100 nmoles/l, American Diagnostica Inc.) was added
nd incubated for another 10 min at 37°C. An aliquot of
00 l from the mixture was added to S2765 Xa substrate
5 mmoles/l) and incubated at 37°C for 20 min; fXa activity
as detected at absorbance 405 nm. As control, cells alone
r C5a-stimulated cells without pTF were used.
estern blotting. Western blotting was performed as
escribed (18). After measuring protein concentrations in
upernatant pTF and microparticle pTF samples from each
ocation, plasma was subjected to SDS-PAGE, and the
eparated proteins were transferred onto nitrocellulose
embranes. Each gel well contained 20 g of protein as
easured by Comassie blue protein assay. Membranes were
locked with 5% nonfat dry milk in Tris-buffered saline
ontaining 0.05% Tween 20, then incubated with rabbit
nti-human TF immunoglobulin G (IgG) (American Di-
gnostica Inc.) or rabbit anti-human fVIIa IgG (Abcam,
nc., Cambridge, Massachusetts), followed by alkaline
hosphatase-conjugated rabbit IgG secondary antibodies
Abcam, Inc.), and visualized with phosphatase substrate,
CIP/NBT (KPL, Gaithersburg, Maryland) (n  6). One
lot was stained with an antibody to alternatively spliced
uman TF (17).
Digitized Western blot band images were quantified with
uantity One Software 4.5.2 (Bio-rad Laboratories, Her-
ules, California) using the volume rectangular tool and
nalyzed for volume density (n  3). The volume density
as defined as the total sum of intensity (inverted range 0 to
55 for each pixel) of all the pixels in the volume divided by
he area of the volume and is reported as intensity/mm2. A
ackground volume density was subtracted from each band.
hrombin generation. Prothrombin fragment F1.2 and
hrombin-antithrombin complex (TAT) were measured to
ompared with pTF concentrations in wound and perfusate
lasma using kits (Dade Behring Inc., Newark, Delaware).
echanistic studies. pTF was measured in plasma from
re-bypass, perfusate, and wound samples by ELISA.
lasma human monocyte chemotactic protein-1 was mea-
ured by human MCP-1 immunoassay Quantikine assay kit
R & D Systems, Minneapolis, Minnesota).
Plasma taken from each sample location (2.0 ml) was
ixed with unstimulated or C5a-stimulated sample mono-
uclear cells (2  106/ml) in various combinations and then
ncubated for 10 min at 37°C with fVII (10 nmoles/l) andalcium (5 mmoles/l). For control purposes a similar volume
f buffer was used instead of plasma or cells.
Stimulated and unstimulated donor mononuclear cells (2
106/ml) were also incubated with 1.46 pmoles/l wound
TF or fractions of wound pTF for 10 min at 37°C to
etermine the effects of monocyte activation on fVII acti-
ation at equivalent TF concentrations. Factor VIIa was
easured after fVII (10 nmoles/l) and CaCl2 (5 mmoles/l)
ere added and incubated 10 min longer.
igure 1. (A) Concentrations of soluble plasma tissue factor (pTF) (filled
ars) and MCP-1 (open bars) in plasma harvested before cardiopulmonary
ypass (CPB) (Pre) and simultaneously from the perfusion circuit (Perf)
nd pericardial wound (Wnd) during CPB. Values are means  SEM, n
7. p  0.0002 and 0.0009 for Wnd pTF versus Pre pTF and Perf pTF,
espectively. p  0.000017 and 0.0000093 for Wnd MCP-1 versus Pre
CP-1 and Perf MCP-1, respectively. p  0.18 for Pre pTF versus Perf
TF and for Pre MCP-1 versus Perf MCP-1. (B) Wound pTF with
5a-stimulated mononuclear cells (2  106/ml) from all locations (open
ars) and unstimulated wound mononuclear cells (filled bars) convert all
vailable factor VII (fVII) to fVIIa. Unstimulated monocytes from pre-
ypass and perfusate samples partially activate fVII. Values are means 
EM, n  6.Donated platelets (2  106/ml) were preincubated with
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Monocytes and Plasma TF Activate Factors VII and X August 16, 2005:707–13FLLRN-NH2 (20 moles/l) for 10 min at 37°C and then
ncubated with wound pTF for 10 min at 37°C. Factor VII
10 nmoles/l) and CaCl2 (5 mmoles/l) were added and
ncubated 10 min longer, after which fVIIa was measured.
tatistical analysis. Data are expressed as mean  SEM.
omparisons between serial samples taken from different
roups are made using one-way ANOVA. Comparisons for
arious combinations of different plasma and monocyte
amples from patients are made by paired t tests. Correla-
ion coefficients are calculated by ANOVA (StatView ver-
ion 4.51, Abacus Concepts Inc., Berkeley, California).
ESULTS
oncentrations of pTF and MCP-1 in blood samples
btained from each sampling location are shown in Figure
A. Note that the highest concentrations of pTF (3.64 
.45 pmoles/l) and MCP-1 (29.5.  2.1 pmoles/l) are in
ound plasma (n  7). Respective mean concentrations
ere 0.71  0.65 and 2.8  1.2 pmoles/l in pre-bypass
lasma and 1.31 0.47 and 3.3 1.4 pmoles/l in perfusate
n  7).
Wound pTF with unstimulated wound monocytes and
5a-stimulated monocytes from each sample location con-
ert all available fVII (10 nmoles/l) to fVIIa (Fig. 1B).
nstimulated pre-bypass and perfusate monocytes fail to do
o. Interestingly, after adding fVII (10 nmoles/l) and CaCl2
5 mmoles/l), wound monocytes (2  106/ml) with pre-
ypass plasma generated 2.02  2.82 nmoles/l fVIIa; thus,
ound monocytes without increased pTF are weakly pro-
oagulant (n  5, data not shown).
Resting and stimulated (20 nmoles/l SFLLRN-NH2)
latelets with wound pTF generated 2.01  0.02 and 2.57
0.11 nmoles/l fVIIa, respectively (data not shown, n 3).
When wound pTF (250 l) was fractionated for 30 min
t 17,570 g (16), supernatant pTF contained 3.58  1.05
81.7%) pmoles/l TF antigen and microparticle pTF con-
ained 0.80  0.23 (18.3%) pmoles/l (n  4) (Fig. 2A).
hen the same wound pTF was centrifuged at 260,000 g
or 4 h (17), TF antigen in the lower, pigmented superna-
ant fraction of diluted wound pTF (2 ml) was 6.98  0.51
moles/l (87.5%) and was 1.00  0.12 pmoles/l (12.5%) in
he microparticle pellet (n  4) (Fig. 2A).
Equal concentrations of TF antigen (1.46 pmoles/l) taken
rom wound pTF, wound microparticle pTF or wound
upernatant pTF were combined with donor unstimulated
r C5a-stimulated mononuclear cells (2  106/ml) (n  3).
fter adding fVII (10 nmoles/l) and CaCl2 (5 mmoles/l),
VIIa was measured (Fig. 2B). Compared with micropar-
icle pTF, wound pTF and supernatant pTF strongly
atalyzed fVIIa production with unstimulated and stimu-
ated mononuclear cells; however, only part of the available
VII (10 nmoles/l) was activated. Mononuclear cell stimu-
ation modestly increased Factor VIIa generation with all
F preparations.
Figure 3 (left panel) shows the molecular weight distri-ution of TF antigen in fractionated samples of pTF taken
rom each location in a representative patient. Wound
upernatant pTF is markedly increased compared with
re-bypass or perfusate supernatant pTF and with all
icroparticle pTF samples. All TF proteins migrate at Mr
47.5 kDa except recombinant TF (Mr  33 kDa). An
ntibody to alternatively spliced human TF, which cross-
eacted with 47 kDa standard TF antigen (American
iagnostica Inc.), showed the presence of a 31 kDa band
blot not shown).
igure 2. (A) Tissue factor antigen in microparticle pTF (mpTF) and
upernatant pTF (spTF) derived from the same wound pTF processed as
escribed by Nieuwland et al. (16) (filled bars) or Bogdanov et al. (17) (open
ars). p 0.021, mpTF versus spTF, filled bars; p 0.00041, mpTF versus
pTF, open bars, n  4). (B) fVIIa generated from unstimulated and
5a-stimulated donor mononuclear cells incubated with 1.46 pmoles/l of
ound pTF, wound microparticle TF (mpTF) or wound supernatant TF
spTF) (n  3). p values for fVIIa production between stimulated and
nstimulated monocytes are 0.002, wound mpTF; 0.043, wound spTF; and
.069, wound pTF. p values for wound mpTF versus wound spTF or wound
TF for stimulated and unstimulated monocytes ranged from 0.000 to 0.005;
values for wound spTF versus wound pTF were 0.270 and 0.407. Solid bars
unstimulated; open bars  stimulated. Abbreviations as in Figure 1.Figure 3 (right panel) shows the molecular weight distri-
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hown in the left panel. Note that most of the fVII/VIIa
omplex in wound plasma is associated with microparticle
TF.
Figure 4 shows the amount of fX converted to fXa by the
wo fractions of pTF from each sample location. The
ractions, supernatant pTF and microparticle pTF, were
entrifuged 30 min at 17,570 g (16) after combination with
onor unstimulated or C5a-stimulated monocytes (2 
06/ml). Although wound microparticles contain high con-
entrations of fVII(VIIa), activated mononuclear cells with
ound supernatant pTF more readily activate fX (p 
.013; n  3). The same plasma centrifuged at 260,000 
provided identical results (data not shown).
The correlation (r) between wound pTF concentrations
nd prothrombin fragment F1.2 in wound plasma is 0.944
n  7) (Fig. 5A). The coefficient of determination (R2) for
erfusate samples is 0.0136. Figure 5B shows the correlation
etween wound pTF concentrations and TAT (r  0.98).
or the perfusate sample R2 is 0.126.
ISCUSSION
his study supports our hypothesis and establishes a central
ole for wound pTF and activated mononuclear cells in the
eneration of thrombin in the pericardial wound during
ardiac surgery using CPB. Activated monocytes with
ound pTF convert all available fVII to fVIIa, wound pTF
oncentrations are sufficient for generation of fVIIa, wound
ononuclear cells are activated, wound monocytes alone
eakly activate fVII, a strong correlation exists between
ound pTF levels and thrombin formation, and wound
igure 3. Western blots probed using anti-tissue factor (TF) (left panel)
nd anti-factor VII(fVII) (right panel) from fractionated samples of
lasma tissue factor (pTF) taken from three locations in a representative
atient (one of three). Molecular standards appear at the left in each panel.
lasma TF from each location was separated as described (16) into
icroparticle (mpTF) and supernatant (spTF) fractions. Note that all TF
roteins migrate at 47.5 kDa except for recombinant soluble TF (rTF).
he highest amount of TF is in the supernatant fraction of wound pTF. In
ontrast, the microparticle fraction of wound pTF contains the largest
mount of fVII/fVIIa complex (right panel).upernatant pTF contains significantly more pTF antigen
w
Fhan wound microparticle pTF. Although wound micropar-
icle pTF binds fVII(VIIa) with high affinity, wound super-
atant pTF/fVII(VIIa) complex has a larger role in fX
ctivation. These observations explain the paradox of rapid
onocyte procoagulant activity in the wound (8) and
elayed monocyte procoagulant activity in the perfusion
ircuit (19); where few monocytes are activated, pTF con-
entrations are low and monocyte synthesis of TF has not
et occurred (20).
Previous studies demonstrated increased concentrations
f pTF in the pericardial wound of cardiac surgical patients
equiring CPB (6,10). Our studies confirm this observation
nd predominant thrombin generation in the pericardial
ound (3,6,8–10). Sturk-Maquelin et al. (10) demonstrated
role for procoagulant microparticles with “exposed” TF in
ound thrombin generation and found a median of 77%
range 20% to 78%) of wound non–cell-bound TF is
ssociated with microparticles. Our study shows only 12% to
8% of wound pTF is associated with wound microparticles.
his discrepancy may reflect differences in method of
reparation or sampling time. Moreover, we find that with
ononuclear cells, wound microparticle pTF is less efficient
n activation of fVII. In addition, although microparticles
ind more fVII(fVIIa), wound microparticle pTF/
VII(fVIIa) complex activates less fX than mononuclear
ells with wound supernatant pTF/fVII(fVIIa). These ob-
ervations and the demonstration of fVII catalytic activity by
icroparticle-free wound supernatant pTF associated with
ononuclear cells are novel; others (21–23) have demon-
trated transfer of microparticle TF to monocytes, neutro-
hils, platelets, and aggregates of these components, but not
ransfer of microparticle-free supernatant TF.
The mechanisms of pTF activation of fVII are unknown,
nd many variables may be involved. The molecular weight
nd concentration of TF antigen may be important; recom-
igure 4. Activation of fX by fractionated wound pTF and C5a-stimulated
onor mononuclear cells (open bars) and unstimulated monocytes (filled
ars) taken from each location. Paired t test p values for fXa generation by
ach sample mpTF, spTF pair (n  6 pairs) ranged from 0.0004 to 0.060,
ith only the unstimulated pre-bypass pairp 0.05. Abbreviations as in
igure 3.
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Monocytes and Plasma TF Activate Factors VII and X August 16, 2005:707–13inant TF (kDa 33) is less efficient than wound pTF and
ound supernatant pTF (kDa 47) (data not shown). With
timulated mononuclear cells, 1.46 pmoles/l wound pTF
nd wound supernatant pTF failed to convert all available
VII to fVIIa. Furthermore, wound microparticle TF (kDa
7) in combination with stimulated mononuclear cells does
ot efficiently catalyze fVII activation. Microparticle TF
ay not associate with mononuclear cells to bind fVII or
ay impair association of microparticle-bound TF with
ononuclear cells; in either event, activation of fVII is
iminished as compared with supernatant pTF. The larger
ononuclear cell may spatially orient microparticle-free
upernatant pTF better for fVII capture and assembly of
upernatant pTF/fVII(fVIIa) complex, as compared to free
igure 5. Correlation between wound pTF and prothrombin fragment
1.2 (A) and thrombin antithrombin complex (B) in wound samples
uring CPB. Abbreviations as in Figure 1.icroparticles or platelet-bound TF. In addition, activated sononuclear cells express the CD11b receptor that binds fX
24); thus, mononuclear cells may also facilitate assembly of
he supernatant pTF/fVII(fVIIa)/fXa complex for cleavage
f prothrombin. The possible importance of pTF concen-
ration, pTF molecular weight, phospholipid platform for
TF, cell activation, spatial orientation, and substrate bind-
ng is consistent with the observation that in diabetic
atients platelet microparticles exposing TF are not proco-
gulant (25).
This study does not address the composition or sources of
ound pTF, which may or may not be unique to cardiac
urgery with CPB. Increased concentrations of circulating
TF occur in a variety of diseases associated with intravas-
ular coagulation, including unstable angina and myocardial
nfarction, diabetes, sepsis, and some malignancies
11,21,26,27). However, pTF may not be the same between
iseases. Presumably all procoagulant microparticles or
icroparticle-free protein TF fragments contain the 219-
mino-acid extracellular domain that complexes with fVII
17,28). If microparticle-bound TF and microparticle-free
rotein fragments in pTF differ between procoagulant
iseases (26), the abilities of these molecules to capture fVII
lso may differ. The present study raises the possibility that
irculating protein fragments of pTF and peripheral mono-
uclear cells activated by complement, cytokines, or other
gonists may generate thrombin in procoagulant diseases
hat have an inflammatory component.
Bogdanov et al. (17) described recombinant alternatively
pliced human TF, which has procoagulant activity and
hich retains the extracellular domain of cellular TF joined
o a novel terminus not incorporated into a phospholipid
ayer. Ruf et al. (29) demonstrated that recombinant TF
rotein, TF1-219, which lacks transmembrane and intracel-
ular domains, retains enhanced catalytic activity when
omplexed with fVIIa but does not form a stable relation-
hip with a phospholipid surface (29). Partial activation of
VII by recombinant TF (Morrissey) with activated mono-
uclear cells is consistent with this observation. A secure
ransmembrane anchor for the extracellular domain of TF
ay be necessary for efficient capture of fVII. Nevertheless,
ur data suggest that mononuclear cells also may provide the
est platform for assembly of truncated forms of pTF and
VII complexes.
Cellular TF is present in all exposed tissues in the cardiac
urgical wound except pericardium (7,8). Thus, the propor-
ionate contributions of cellular TF, wound pTF associated
ith activated peripheral mononuclear cells, and non–cell-
ound TF exposed on microparticles, platelets, leukocytes,
nd platelet-leukocyte aggregates to generate thrombin in
eparinized pericardial wound blood are unknown. When
ound blood is washed, perfusate monocytes and low pTF
oncentrations weakly activate fVII. Thus, washing or
iscarding pericardial wound blood reduces circulating
hrombin.
Generation of thrombin during CPB produces a con-
umptive coagulopathy that causes most of the nonsurgical
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ociated with cardiac surgery and all applications of extra-
orporeal circulation (30,31). Despite elevated wound con-
entrations of TF pathway inhibitor (6), thrombin is
roduced progressively during CPB (6,8,10). Pericardial
lood cannot always be washed or discarded during complex
ardiac operations; therefore, a means to suppress thrombin
eneration in the pericardial wound remains an important
nd worthy goal. The present study indicates that wound
TF and activated mononuclear cells are major targets for
his effort.
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